UAE Investors Target $39.4B GLP-1 Market Amid Healthcare Sector Weakness
Despite a challenging start to the year for the healthcare sector, UAE investors are increasingly focusing on the high-growth potential of the GLP-1 drug market, projected to reach $39.4 billion in 2026.
The broader healthcare sector has declined 5.5% year-to-date, underperforming the S&P 500, which is down 3.3%. However, performance within the sector has diverged significantly, highlighting a growing gap between leading and lagging companies.
Pharma Giants Outperform Amid Market Volatility
Several major pharmaceutical companies have delivered strong gains, including Moderna (+65%), Johnson & Johnson (+16.8%), Merck (+14.4%), Pfizer (+12.4%), and Gilead Sciences (nearly +16%).
According to Josh Gilbert of eToro, investors are increasingly favouring companies with strong pipelines, stable earnings, and clear growth catalysts. “Healthcare is becoming a stock-picker’s market,” he noted, emphasising the importance of selectivity amid macroeconomic uncertainty.
GLP-1 Market Presents Long-Term Opportunity
The GLP-1 obesity drug segment remains a major growth driver, with global sales expected to exceed $100 billion by the end of the decade. However, short-term challenges are emerging for key players.
Shares of Novo Nordisk have fallen 24% year-to-date following weaker sales guidance and disappointing trial results for its next-generation obesity drug, CagriSema. Similarly, Eli Lilly has declined 14% amid valuation concerns and uncertainty around market size.
A recent agreement with US authorities to reduce GLP-1 drug prices by 25–35% is also expected to impact revenues, potentially cutting combined US obesity drug sales by $2–3 billion this year.
Emerging Players and Digital Health Trends
New entrants are reshaping the competitive landscape. Hims & Hers Health has gained attention through its partnership with Novo Nordisk, enabling direct-to-consumer access to GLP-1 treatments via digital platforms. The company has built a subscriber base of 2.5 million, reflecting rising demand for accessible, tech-driven healthcare solutions.
Beyond pharmaceuticals, momentum is building in digital health and wearable technology. WHOOP recently secured $575 million in funding at a $10.1 billion valuation, with backing from investors including Mubadala, Qatar Investment Authority, Abbott, and Mayo Clinic. The company has indicated that a potential IPO could follow.
Sector Outlook Remains Strong
Despite near-term pressures, the healthcare sector continues to present a compelling investment case. Its defensive nature remains attractive in volatile markets, while long-term structural trends—including GLP-1 innovation and digital health adoption—are expected to drive sustained growth.
As investors navigate a complex landscape, the shift towards selective investing and emerging healthcare technologies is set to define the sector’s trajectory in the coming years.
